SCHEMBL74259

SCHEMBL74259

Cc1[c]cccc1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7459931 0.73 ALDH1A1 (0.39) —
SCHEMBL19022 0.72 — —
SCHEMBL22115865 0.72 — —
SCHEMBL2972 0.72 — —
SCHEMBL695988 0.69 PDCD1 (0.39) —
SCHEMBL6754033 0.69 — —
SCHEMBL6607475 0.69 CYP3A4 (0.46) —
SCHEMBL15414904 0.69 CYP3A4 (0.39) —
SCHEMBL3596578 0.69 CYP3A4 (0.39) —
SCHEMBL5653014 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107974080-B Polyamide moulding compositions and multilayer structures made therefrom EMS专利股份公司 2021-07-20 — — CN claimed
CN-112881568-A Method for simultaneously determining multiple associated harmful substances in food thermal processing 大连工业大学 2021-06-01 — — CN claimed
EP-3523290-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY Novartis AG (CH) 2019-08-14 — — EP claimed
EP-3312224-B1 POLYAMIDE MOULDING COMPOSITION AND MULTI-LAYERED STRUCTURE MADE HEREFROM EMS PATENT AG (CH) 2018-12-26 — — EP claimed
EP-3397756-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY Novartis AG (CH) 2018-11-07 — — EP claimed
CN-107974080-A Polyamide moulding composition and the sandwich construction being made from it EMS专利股份公司 2018-05-01 — — CN claimed
EP-3312224-A1 POLYAMIDE MOULDING COMPOSITION AND MULTI-LAYERED STRUCTURE MADE HEREFROM EMS-PATENT AG (CH) 2018-04-25 — — EP claimed
WO-2018059549-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY NOVARTIS AG (CH) 2018-04-05 — — WO claimed
WO-2017114497-A1 IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY NOVARTIS AG (CH) 2017-07-06 — — WO claimed
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 — — US claimed
WO-2000069832-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRYMIDINONES USEFUL AS ANTICOAGULANTS PHARMACIA CORPORATION (US) 2000-11-23 — — WO claimed
WO-2000069833-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS PHARMACIA CORPORATION (US) 2000-11-23 — — WO claimed
WO-2000040558-A1 ASPARTIC PROTEASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-07-13 — — WO claimed
EP-0827507-B1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM CA LTD (CA) 1999-06-16 — — EP claimed
EP-0827507-A1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 1998-03-11 — — EP claimed
US-5705594-A Polyamine crosslinking agent formulation and its preparation BAYER AKTIENGESELLSCHAFT (DE) 1998-01-06 — — US claimed
EP-0780418-A2 Triamines and a process for their preparation BAYER AG (DE) 1997-06-25 — — EP claimed
WO-1996031527-A1 PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) 1996-10-10 — — WO claimed
US-5024786-A Having good build up and resistance to staining SANDOZ LTD. (CH) 1991-06-18 — — US claimed
EP-0314630-A2 Detergent compositions SANDOZ AG (CH) 1989-05-03 — — EP claimed
Send feedback